PhII Study STA-9090 as Second or Third-Line Therapy for Metastatic Pancreas Cancer
Status:
Terminated
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Heat shock protein (HSP)90 inhibitor STA-9090 may stop the growth of tumor cells
by blocking some of the proteins needed for cell growth. PURPOSE: This phase II trial is
studying how well hsp90 inhibitor STA-9090 works as second- or third-line therapy for the
treatment of patients with metastatic pancreatic cancer.